Call the knowledgeable and helpful staff at Glamoi Med Spa at (212) 433-4526 for more information
Dose-dependent hypoglycemia risk exists, particularly when combined with insulin or sulfonylureas
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and increased by 2.5 mg every 4 weeks up to a maintenance dose of 5-15 mg based on tolerability and therapeutic response
If you have a very large prostate (above 80 grams), have a prominent median lobe, or have bladder stones or bladder tumors, UroLift is not recommended
Scalabrino G, Carpo M, Bamonti F, Pizzinelli S, DAvino C, Bresolin N, et al